As of Friday close, Bionano Genomics Inc.’s (NASDAQ:BNGO) stock was up $0.21, moving up 14.89 percent to $1.62. The average number of shares traded per day over the past five days has been 9,152,900 shares. 2 times new highs have been achieved over the past 5 days, with a $0.0600 gain in that time frame. In the last twenty days, the average volume was 7,139,930, while in the previous 50 days, it was 7,272,778.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .
Since last month, BNGO stock retreated -24.65%. Shares of the company fell to $1.1600 on 05/12/22, the lowest level in the past month. A 52-week high of $9.12 was reached on 01/03/22 after having rallying from a 52-week low of $1.16. Since the beginning of this year, BNGO’s stock price has dropped by -45.82% or -$1.3700, and marked a new high 1 time. However, the stock has declined by -82.24% since its 52-week high.
Bionano Genomics Inc. (BNGO) last reported insider trading activity 166 days ago on Nov 29. Holmlin R. Erik, the President and CEO of the company, purchased of 5,025 shares for $3.99 on Nov 29. It resulted in a $20,037 investment by the insider.
The stock’s beta is 2.17. Besides these, the trailing price-to-sales (P/S) ratio of 28.06, the price-to-book (PB) ratio of 1.25.
In the recent quarter, Bionano Genomics Inc.’s quick ratio stood at 12.10, while its current ratio was 13.00, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the recent quarter was 0.01, and the total debt-to-equity ratio was 0.01. On the profitability front, the trailing twelve-month gross margin is 21.60% percent. Based on annual data, BNGO earned $3.87 million in gross profit and brought in $17.98 million in revenue.
According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. BNGO’s revenue rose 44.39% to $6.3 million during the quarter, while net income inched up to $5.7 million. During the quarter, the company generated -$27.41 million in EBITDA. The liabilities of Bionano Genomics Inc. were 37.03 million at the end of its most recent quarter. The value of shareholders’ equity is $289.7 million.
This quick technical analysis looks at Bionano Genomics Inc.’s (BNGO) price momentum. With a historical volatility rate of 166.73%, the RSI 9-day stood at 49.03% on 13 May.
With respect to its five-day moving average, the current Bionano Genomics Inc. price is up by +3.85% percent or $0.0600. At present, BNGO shares trade -21.74% below its 20-day simple moving average and -49.53% percent below its 100-day simple moving average. However, the stock is currently trading approximately -18.59% below its SMA50 and -73.40% below its SMA200.
Stochastic coefficient K was 33.65% and Stochastic coefficient D was 18.18%, while ATR was 0.1904. Given the Stochastic reading of 64.91% for the 14-day period, the RSI (14) reading has been calculated as 45.32%. As of today, the MACD Oscillator reading stands at -0.1256, while the 14-day reading stands at -0.1656.